Horizon Europe (2021 - 2027)

Harnessing an energy-expending, appetite-suppressing fat-brain axis to unlock novel pharmacotherapies: HEAT-UP

Last update: Mar 22, 2023 Last update: Mar 22, 2023

Details

Locations:Denmark
Start Date:Sep 1, 2023
End Date:Aug 31, 2028
Contract value:EUR 2,000,000
Sectors:Health, ResearchHealth, Research
Categories:Grants
Date posted:Mar 22, 2023

Associated funding

Associated experts

Description

Programme(s): HORIZON.1.1 - European Research Council (ERC) 

Topic(s): ERC-2022-COG - ERC CONSOLIDATOR GRANTS

Call for proposal: ERC-2022-COG

Funding Scheme: ERC - Support for frontier research (ERC)

Grant agreement ID: 101088636

Objective:

Obesity and cardiometabolic diseases are global crises that threaten to cripple healthcare infrastructures. These disorders originate from an excess calorie burden caused by consuming too much food and expending too little energy. Yet despite recent advances in obesity drugs, weight-lowering pharmacotherapies only reach about half the efficacy of surgical interventions. This difference could be due to existing drugs only acting to reduce food intake and not boost calorie-burning. Therefore, I believe our discovery of a leptin-independent signaling axis between adipose tissue (AT) and the central nervous system (CNS) that both decreases food intake and increases energy expenditure poses a breakthrough in obesity research. We uncovered this axis through receptor profiling and human genetic association studies and engineered a highly selective agonist that significantly decreases bodyweight and improves glucose and lipid homeostasis in obese mice. Our preliminary data have already led to a spinout company. However, the physiological signaling mechanisms of this receptor in AT and the CNS that shape systemic energy balance through peripheral calorie-burning and central control of food intake remain unknown. Thus, in HEAT-UP, we will delineate AT and CNS receptor circuits with single cell resolution and functionally test this signaling in 3D cultures of mouse and human AT. Tissue-specific contributions to whole-body metabolism will be assessed by combining our proprietary, selective agonist with state-of-the-art viral, genetic, and surgical manipulation of the receptor and neuronal wiring in AT and the CNS. Viral and genetic cell-labeling strategies will be used to characterize novel secretory cells that we found in mouse and human AT to contain the ligand for this receptor. Collectively, these studies will provide a comprehensive, physiological overview of a previously unknown fat-brain signaling axis and insight into its potential for counteracting metabolic diseases.

Want to unlock full information?
Member-only information. Become a member to access projects awards, find the right consortia partners, subcontractors and more.